Antitumor Effect of Ruthenium(II) with 2-Mercaptothiazoline Ligand Complex in Murine Melanoma Model
Open Access
- 4 August 2026
- journal article
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (32) , 47570-47578
Abstract
Ruthenium-based complexes have been explored as promising alternatives in antineoplastic therapy due to their enhanced selectivity for cancer cells. In this context, the present study evaluated the antitumor potential of the ruthenium complex [Ru(mtz)(dppe)2]PF6, named RuMTZ, in C57BL/6 mice bearing B16-melanoma, as well as its toxicity. In addition to tumor weight and mitotic frequency, cleaved caspase-3, γH2AX, and MAPK/ERK expression levels were analyzed by immunohistochemistry. The toxicity of the treatments was assessed through alterations in body and organ weight, biochemical parameters of liver and kidney function, and genotoxicity in bone marrow cells. RuMTZ led to a significant reduction in mitotic frequency and tumor weight, with a tumor growth inhibition rate equivalent to 94.9%. The antimelanoma activity of RuMTZ was accompanied by increased levels of cleaved caspase-3, γH2AX, and MAPK/ERK. These data indicate that RuMTZ induced DNA strand breaks, which may be, at least in part, related to the induction of caspase- and ERK1/2-mediated apoptosis. RuMTZ treatment, unlike cisplatin, showed no weight loss or impairment of liver and kidney functions. However, similar to other metallopharmaceuticals, it caused myelosuppression, evidenced by the absence of erythrocytes. These findings support the promising antitumor activity of RuMTZ, indicating its potential as a metallodrug.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (302203/2019-2)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2017/15850-0)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (8882.36731/2019-01)
This publication has 58 references indexed in Scilit:
- Exploring the Future of Metal‐Based Anticancer Agents: A Comprehensive Review of Ruthenium‐Based ComplexesChemistrySelect, 2025
- H2AX: A key player in DNA damage response and a promising target for cancer therapyBiomedicine & Pharmacotherapy, 2024
- Ruthenium(II) complex with 2-mercaptothiazoline ligand induces selective cytotoxicity involving DNA damage and apoptosis in melanoma cellsJBIC Journal of Biological Inorganic Chemistry, 2024
- Target based chemotherapeutic advancement of ruthenium complexesCoordination Chemistry Reviews, 2021
- Caspase‐3: Structure, function, and biotechnological aspectsBiotechnology and Applied Biochemistry, 2021
- Anti-Melanoma Activity of Indomethacin Incorporated into Mesoporous Silica NanoparticlesPharmaceutical Research, 2020
- Ru/Fe bimetallic complexes: Synthesis, characterization, cytotoxicity and study of their interactions with DNA/HSA and human topoisomerase IBArchives of Biochemistry and Biophysics, 2017
- Targeting MAPK pathway in melanoma therapyCancer and Metastasis Reviews, 2013
- In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cellsBiomedicine & Pharmacotherapy, 2009
- Guidelines for the conduct of micronucleus assays in mammalian bone marrow erythrocytesMutation Research/Genetic Toxicology, 1987